MRTX

Mirati Therapeutics, Inc. (MRTX) | Rumor.io

Mirati Therapeutics

MRTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Jan 23

Mirati Therapeutics, Inc. (MRTX) has been halted for additional information requested by NASDAQ.
Bristol Myers Squibb (BMY) has completed its acquisition of MRTX, strengthening and diversifying its oncology portfolio.
The acquisition is expected to result in a $0.35 per share charge for BMY.

Generated by AI

Sentiment

Of the messages about MRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% 0
Bearish	—	—	0%	0% 0

Bullish· Oct 9

Mirati Therapeutics, Inc. (MRTX) has two promising P3 programs with significant market potential, valued at $1.0B+ each.
The acquisition of MRTX by a major player for $5.8B at a $1B revenue estimate for Kras is a bullish sign for the company's future growth.
The stock is undervalued by 30% and is expected to rebound towards $90, with a strong resistance point at $56/s that could lead to a significant price increase.

Bearish· Oct 9

The company's management and board of directors have a history of questionable behavior, making it difficult for investors to trust the company.
The buyout valuation of $58 per share is disappointing and suggests that the company may not be worth as much as investors had hoped.
The stock's performance has been negatively impacted by a series of downgrades and sell-offs, including a recent downgrade to neutral from buy and a 5.09% price drop.

Generated by AI

Topics

Of the messages about MRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Dec 8

JP Morgan analyst Anupam Rama downgrades Mirati Therapeutics from $94 to $65 with a Neutral rating.
SVB Leerink cuts Mirati Therapeutics price target to $85.00.
Piper Sandler maintains Mirati Therapeutics with an Overweight rating and lowers the price target from $110 to $84.

Announcements· Oct 10

Bristol Myers Squibb buys San Diego cancer therapy Mirati Therapeutics for $4.8B.
Bristol Myers Squibb buys Mirati for up to $5.8B as I-O giant branches out into targeted therapy for cancer.
$MRTX Q4 2023: Bristol Myers Squibb buys Mirati at $58/share, $4.8b total, with Mirati's oncology portfolio bolstering BMS's oncology.

Technical Analysis· Sep 15

The author sees a potential buy zone for $MRTX at $10.30 and suggests selling when the trend breaks.
A bearish pattern formation is observed in $MRTX, with the stock currently in consolidation mode.
The author identifies a potential reentry point for $MRTX at $10.40, with a possible triple top formation on the 1-minute candles.

Generated by AI

Community

Of the messages about MRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	50.77%	39.27%
Newcomers	0%	0%	49.23%	60.73%

Regulars· Oct 10

Mirati Therapeutics ($MRTX) is likely to be acquired by Bristol Myers Squibb (BMY) at a price of $58 per share, as the market has already priced in a 60% increase in the stock's value prior to the acquisition announcement.
The current market price of $MRTX is around $57, indicating a near-certain acquisition, with the US FTC not expected to block the deal.
Mirati Therapeutics' stock is currently trading with a 7-year Call Volume Ratio (CVR) of $12, which the market is ignoring, as the focus is on the FDA milestone and the potential for the stock to be acquired.

Newcomers· Oct 9

Mirati Therapeutics is being acquired by Bristol-Myers Squibb for up to $5.8 billion, with the deal expected to close in the first half of 2024.
The contingent value right (CVR) included in the deal has the potential to be worth $12 per share, making it a high-risk, high-reward investment.
The acquisition strengthens Bristol-Myers' overall I-O franchise and suggests that targeted approaches to non-small cell lung cancer (NSCLC) are a valuable area of research.

Generated by AI

Also Discussed

Investors talking about MRTX also mention

#	Name	Attention
1	SGEN - Seagen Inc.	——
2	Amgen Inc.AMGN	0.01%+0
3	SWTX - SpringWorks Therapeutics, Inc.	——
4	Incyte Corp.INCY	0%new
5	Arcus Biosciences, Inc.RCUS	0%new
6	Oric Pharmaceuticals, Inc.ORIC	0%0
7	Kura Oncology, Inc.KURA	0%+0
8	MYOV - Myovant Sciences Ltd.	——
9	TG Therapeutics Inc.TGTX	0.01%+0
10	KRTX - Karuna Therapeutics, Inc.	——